Cardiovascular Prostheses
Cardiovascular prostheses having particulate structures that are adapted to induce modulated healing of damaged or diseased cardiovascular tissue and, thereby, associated structures, when administered thereto. The particulate structures include a biological component and a polymer component. The biological component is in the form of a composition and includes decellularized amniotic membrane and placental tissue. The biological composition can also include a plurality of exosomes derived from mesenchymal stem cells or embryonic stem cells. The polymer component includes poly(glycerol sebacate) (PGS).
1 . A cardiovascular prosthesis, comprising:
a particulate structure comprising a plurality of particulate structures, each of said plurality of particulate structures comprising a biological component and a polymer component,
said biological component comprising a biological composition comprising decellularized amniotic membrane tissue,
said polymer component comprising a polymer composition comprising poly(glycerol sebacate) (PGS).
2 . The prosthesis of claim 1 , wherein said biological composition further comprises a plurality of exosomes derived from a cell source selected from the group consisting of mesenchymal stem cells and embryonic stem cells.
3 . The prosthesis of claim 1 , wherein said biological composition further comprises an HMG-CoA reductase inhibitor.
4 . The prosthesis of claim 3 , wherein said HMG-CoA reductase inhibitor comprises (3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid (cerivastatin).
5 . The prosthesis of claim 1 , wherein said polymer composition further comprises poly(ε-caprolactone) (PCL).
6 . The prosthesis of claim 1 , wherein said biological component is encased in said polymer component.
7 . A cardiovascular prosthesis, comprising:
a particulate structure comprising a plurality of particulate structures, each of said plurality of particulate structures comprising a biological component and a polymer component,
said biological component comprising a biological composition comprising decellularized placental tissue,
said polymer component comprising a polymer composition comprising poly(glycerol sebacate) (PGS).
8 . The prosthesis of claim 7 , wherein said biological composition further comprises a plurality of exosomes derived from a cell source selected from the group consisting of mesenchymal stem cells and embryonic stem cells.
9 . The prosthesis of claim 7 , wherein said biological composition further comprises an HMG-CoA reductase inhibitor.
10 . The prosthesis of claim 9 , wherein said HMG-CoA reductase inhibitor comprises (3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acid (cerivastatin).
11 . The prosthesis of claim 7 , wherein said polymer composition further comprises poly(ε-caprolactone) (PCL).
12 . The prosthesis of claim 7 , wherein said biological component is encased in said polymer component.
13 . A cardiovascular prosthesis, comprising:
a particulate structure comprising a plurality of particulate structures, each of said plurality of particulate structures comprising a biological component and a polymer component,
said biological component comprising an extracellular matrix (ECM) composition comprising acellular ECM derived from mammalian tissue selected from the group consisting of amniotic membrane and placental tissue,
said polymer component comprising a polymer composition comprising a polymer selected from the group consisting of polyglycolide (PGA), polylactide (PLA), poly(epsilon-caprolactone) (PCL), polydioxanone and polylactide-co-glycolide.
14 . The prosthesis of claim 13 , wherein said biological composition further comprises a plurality of exosomes derived from a cell source selected from the group consisting of mesenchymal stem cells and embryonic stem cells.
15 . The prosthesis of claim 13 , wherein said biological component is encased in said polymer component.